NYSE$OSCR
Oscar Health Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Oscar Health reported strong results for the fourth quarter and full year 2023, exceeding expectations for the full year and demonstrating progress towards profitability.
Oscar Health announced strong Q4 and full-year 2023 results, with core metrics exceeding expectations. The company delivered on its commitment for Insurance Company Adjusted EBITDA profitability and anticipates consolidated Adjusted EBITDA profitability in 2024. They served over 1.3 million members and are focused on sustainable margin expansion.
- Oscar Health reported strong 2023 results, exceeding expectations for the full year.
- The company delivered on its commitment for Insurance Company Adjusted EBITDA profitability.
- Oscar Health has a clear path to consolidated Adjusted EBITDA profitability in 2024.
- Oscar Health served more than 1.3 million members in 2023.
Headline financials
Revenue & EPS history
Oscar Health · Revenue · Quarterly
$1.43B
Forward guidance
The Company anticipates Total Revenue of $8.3 billion to $8.4 billion, a Medical Loss Ratio of 80.2% to 81.2%, a SG&A Expense Ratio of 20.5% to 21.0%, and Total Company Adjusted EBITDA of $125 million to $175 million.
Tailwinds
- Total Revenue of $8.3 billion to $8.4 billion
- Medical Loss Ratio of 80.2% to 81.2%
- SG&A Expense Ratio of 20.5% to 21.0%
- Total Company Adjusted EBITDA of $125 million to $175 million
- Clear line of sight into consolidated Adjusted EBITDA profitability in 2024
Headwinds
- Actual results may differ materially depending on a number of factors.
- Uncertainty in estimating stock-based compensation expense.
- Dependence on various factors, some of which are outside of Oscar’s control.
- New factors emerge from time to time, and it is not possible for us to predict which will arise.
- Heightened competition in the markets in which we participate
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
+3.7%
Avg return
Earnings day
+5.6%
Avg return
5 days after
+7.5%
Avg return
30 days after
64%
16 / 25 earnings
Positive
+30.0%
Q1 2025
Best reaction
-23.9%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.7% | +22.6% | +36.6% | |
| Q4 2025 | +1.7% | +6.0% | +2.7% | |
| Q3 2025 | -2.8% | -12.8% | -1.5% | |
| Q1 2025 | +30.0% | +28.7% | +18.0% | |
| Q4 2024 | +3.1% | -3.7% | +4.5% | |
| Q3 2024 | -12.9% | -12.8% | +0.4% | |
| Q2 2024 | +7.2% | +4.4% | -1.4% | |
| Q1 2024 | +9.3% | +14.1% | +2.8% | |
| Q4 2023 | +22.7% | +27.5% | +7.7% | |
| Q3 2023 | +23.5% | +24.5% | +42.0% | |
| Q2 2023 | +8.6% | +1.9% | -10.5% | |
| Q1 2023 | -8.8% | -6.6% | +17.8% | |
| Q4 2022 | +21.0% | +36.2% | -3.9% | |
| Q3 2022 | -23.9% | -4.5% | -11.3% | |
| Q2 2022 | +19.9% | +21.1% | -3.7% | |
| Q1 2022 | -8.9% | -2.0% | -25.0% | |
| Q4 2019 | +6.3% | +2.5% | +39.1% | |
| Q4 2021 | +2.4% | +15.6% | +21.9% | |
| Q3 2020 | -2.4% | -6.3% | -12.7% | |
| Q3 2021 | -23.3% | -25.2% | -33.0% | |
| Q2 2020 | -16.4% | -11.8% | +19.4% | |
| Q2 2021 | -0.9% | -12.0% | +17.9% | |
| Q4 2020 | +15.2% | +14.5% | +23.1% | |
| Q1 2020 | +15.2% | +14.5% | +23.1% | |
| Q1 2021 | +3.6% | +4.2% | +14.0% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro